Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,281.0
3.0 (0.09%)

 

  • STI Straits Times Index
    3,281.0
    3.0 (0.09%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,595.8
    7.9 (0.50%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    29,056.4
    173.4 (0.60%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,075.5
    1.4 (0.05%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    24,041.3
    108.1 (0.45%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,291.7
    5.6 (0.09%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,250.6
    2.5 (0.11%)
    Index delayed 20 minutes
  • XAO XAO
    7,180.3
    21.7 (0.30%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,723.5M
  • Value: 1,021.1M
  • Rise: 204
  • Fall: 116
  • Unch: 499

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
AsiaPhos0.047+0.019
Golden Agri-Res0.235-
OEL0.029+0.009
Sincap0.013+0.003
Rex Intl0.192+0.011
AusGroup^0.048+0.001
BlackGoldNatural0.018+0.002
AsiaMedic0.013+0.002
Ley Choon0.022+0.004
GCCP0.009+0.002

World Indices

World Indices
Name Last Change
Nasdaq 9,388.9 +31.8
HSI 29,056.4 +173.4
HSCEI 11,419.9 +91.5
Jakarta 6,291.7 +5.6
Nikkei 225 24,041.3 +108.1
SSE Comp 3,075.5 +1.4
Shanghai A 3,222.5 +1.4
Shanghai B 260.1 +2.0
PSE Comp 0.0
KOSPI 2,250.6 +2.5

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

SANGAMO THERAPEUTICS INC SANGAMO THERAPEUTICS
Updated on 17 Jan 2020 (End of trading day)
Last (USD): 8.370 Change: -0.475 High: 8.980 Remarks: -
Change (%): -5.37 Low: 8.320
Open 8.970 Yesterday's Close 8.844999999999999
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 1,686,375 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.58940 Trailing EPS (USD) e -1.02128 NAV (USD) b 3.6148
PE a - Trailing PE f - Price / NAV b 2.3155
Dividend (USD) d - Cash In Hand (USD) g 1.0030 Issued & Paid-up Shares c 115,938,000
Dividend Yield (%) d - Price / Cash In Hand g 8.345 Treasury Shares h -
Beta - 75 Daysi 1.176 R-Squared - 75 Days(%)i 5.41 Market Cap (M) 970.401
Beta - 500 Daysi 0.033 R-Squared - 500 Days (%)i 0.01 Enterprise Value (M) 657.391
Piotroski F Score 4 Exchange Code SGMO Par Value ( $ ) n.a.
52 Weeks Volatility (%) 77.56 Free Float (%) 99.9
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 07 Nov 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 13 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference SANGAMO THERAPEUTICS INC NASDAQ 970.401 - - 2.3155 -
Industry Biotechnology NASDAQ 2,423.944 408.251 - 6.0398 0.727
Local Peer AMGEN INC NASDAQ 143,489.494 17.094 17.787 13.1317 2.317
Local Peer GILEAD SCIENCES INC NASDAQ 79,679.147 14.607 29.588 3.8672 3.668
Local Peer VERTEX PHARMACEUTICAL NASDAQ 60,643.685 28.928 28.288 11.5437 -
Local Peer BIOGEN INC NASDAQ 51,516.191 11.627 9.548 3.6808 -
Local Peer ILLUMINA INC NASDAQ 47,733.840 57.789 49.058 10.7533 -
Local Peer REGENERON PHARMACEUTICALS INC NASDAQ 42,374.657 17.335 19.762 4.0340 -
Local Peer ALEXION PHARMACEUTICAL INC NASDAQ 25,065.632 323.010 17.048 2.4178 -
Local Peer SEATTLE GENETICS INC NASDAQ 18,681.074 - - 10.4973 -
Local Peer INCYTE CORPORATION NASDAQ 17,339.459 158.362 42.817 7.1576 -
Local Peer BIOMARIN PHARMACEUTICAL NASDAQ 15,855.499 - - 5.1573 -
Local Peer GALAPAGOS NV SPON ADR REPR 1 ORD SHS NASDAQ 14,724.029 - 47.442 5.3271 -
Local Peer ALNYLAM PHARMACEUTICALS INC NASDAQ 13,247.242 - - 8.2430 -
Other Local Peers BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), EXACT SCIENCES CORP (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), 10X GENOMICS INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), MODERNA INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), EXELIXIS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), REPLIGEN CORP (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), IMMUNOMEDICS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), FIBROGEN INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), NATERA INC (NASDAQ), UNIQURE N.V. (NASDAQ), KODIAK SCIENCES INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), EPIZYME INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), SYNTHORX INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), XENCOR INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), VIELA BIO INC (NASDAQ), ARVINAS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), INSMED INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), REGENXBIO INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), CORTEXYME INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), VERACYTE INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), NEXTCURE INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), DERMIRA INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), OPKO HEALTH INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), XBIOTECH INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), INTREXON CORP (NASDAQ), RADIUS HEALTH INC (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), OMEROS CORP (NASDAQ), NANTKWEST INC (NASDAQ), AVROBIO INC (NASDAQ), CYTOKINETICS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), RETROPHIN INC (NASDAQ), IMMUNOGEN INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), ARDELYX INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), KURA ONCOLOGY INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), MACROGENICS INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), AGENUS INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), MERUS B V (NASDAQ), BELLUS HEALTH INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), CABALETTA BIO INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), COMPUGEN (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), PERSONALIS INC (NASDAQ), RECRO PHARMA INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), NEUROINSIGHTS NEUROTECH (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), IVERIC BIO INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), MEDICINOVA INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), GERON CORP (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), KAMADA (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), AFFIMED N V (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), XOMA CORP (NASDAQ), GLYCOMIMETICS INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), CHIASMA INC (NASDAQ), IMV INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), ATHERSYS INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), ARAVIVE INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), NOVAVAX INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), CONTRAFECT CORP (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), SAVARA INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), VERASTEM INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), CHIMERIX INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), ADURO BIOTECH INC (NASDAQ), OTONOMY INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), SESEN BIO INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), COHBAR INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), SYNLOGIC INC (NASDAQ), INFLARX N V (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), ORGENESIS INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), TREVENA INC (NASDAQ), EQUILLIUM INC (NASDAQ), VERMILLION INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), VACCINEX INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), INMUNE BIO INC (NASDAQ), ADVAXIS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), CURIS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), RESTORBIO INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), ZAFGEN INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), EVOGENE LTD (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), SOLIGENIX INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), OCUGEN INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), BIOCARDIA INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), BIONANO GENOMICS INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), ATYR PHARMA INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), VAXART INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), PRECIPIO INC (NASDAQ), SENESTECH INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), BIOCEPT INC (NASDAQ), TOCAGEN INC (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), TROVAGENE INC (NASDAQ), OPGEN INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), SENECA BIOPHARMA INC (NASDAQ), SPHERIX INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ)
Global Peer CSL ASX 136,206.687 50.768 50.768 18.2018 0.884
Global Peer AMGEN-T HKEx 594,184.000 9.032 9.399 6.9364 4.385
Global Peer AGILENT TECHNOLOGIES INC NYSE 27,953.692 88.461 26.101 5.8875 0.678
Global Peer SINO BIOPHARM HKEx 147,105.276 13.729 14.249 4.3809 0.626
Global Peer WUXI BIO HKEx 135,974.714 182.049 142.322 13.9969 -
Global Peer BEIGENE HKEx 102,874.590 - - 10.2644 -
Global Peer GENSCRIPT BIO HKEx 35,347.948 212.573 - 9.9682 -
Global Peer Lonza SGX 5,937.453 7.663 9.330 0.6935 4.766
Global Peer 3SBIO HKEx 28,549.263 18.872 22.971 2.8139 -
Global Peer EMERGENT BIOSOLUTIONS INC NYSE 2,868.229 45.745 667.030 2.7712 -
Other Global Peers HAOHAI BIOTEC (HKEx), ALPHAMAB-B (HKEx), FRONTAGE (HKEx), MYOVANT SCIENCES LTD (NYSE), POLYNOVO LIMITED (ASX), AVITA MEDICAL LTD (ASX), CKLIFE SCIENCES (HKEx), VIVA BIOTECH (HKEx), MESOBLAST LTD (ASX), ASCENTAGE-B (HKEx), KADMON HLDGS INC (NYSE), SINOMAB BIO-B (HKEx), ARCUS BIOSCIENCES INC (NYSE), ESSEX BIO-TECH (HKEx), ASCLETIS-B (HKEx), LEE'S PHARM (HKEx), NEXT SCIENCE LTD (ASX), PFENEX INC (NYSE American), DPHARMA (Bursa), TELIX PHARMACEUTIC (ASX), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), BBI LIFE SCI (HKEx), NANOVIRICIDES INC (NYSE American), NEUREN PHARMACEUTICALS LTD (ASX), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), RESAPP HEALTH LIMITED (ASX), UNI-BIO GROUP (HKEx), PYC THERAPEUTICS LIMITED (ASX), ENZO BIOCHEM INC (NYSE), LINEAGE CELL THERAPEUTICS INC (NYSE American), 22ND CENTURY GROUP INC (NYSE American), IMUGENE LIMITED (ASX), PALATIN TECHNOLOGIES INC (NYSE American), CEL-SCI CORP (NYSE American), CYNATA THERAPEUTICS LTD (ASX), IMMUTEP LTD (ASX), ONCOSIL MEDICAL LIMITED (ASX), SYNTHETIC BIOLOGICS INC (NYSE American), ORTHOCELL LIMITED (ASX), CT ENTERPRISE (HKEx), ISORAY INC (NYSE American), BIOSINO BIO-TEC (HKEx), INVEX THERAPEUTICS LTD NPV (ASX), ANTEOTECH LIMITED (ASX), MEMPHASYS LTD (ASX), KAZIA THERAPEUTICS LIMITED (ASX), BIONOMICS LTD (ASX), BIOTRON (ASX), REGENT PACIFIC (HKEx), ARMATA PHARMACEUTICALS INC (NYSE American), ACTINOGEN MEDICAL LTD (ASX), TALI DIGITAL LIMITED (ASX), GENETIC TECHNOLOGIES (ASX), ORAGENICS INC (NYSE American), ACTINIUM PHARMACEUTICALS INC (NYSE American), EXTRAWELL PHAR (HKEx), IBIO INC (NYSE American), INDIA GLOBALIZATION CAPITAL INC (NYSE American), RHINOMED LIMITED (ASX), CCP TECHNOLOGIES LTD (ASX), PROTEOMICS INTL LABORATORIES LTD (ASX), IMMURON LIMITED (ASX), CELLMID LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), PATRYS LIMITED (ASX), REGENEUS LTD (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), Suntar Eco-City^ (SGX), HOLISTA COLLTECH LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), ADALTA LTD (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), ANATARA LIFESCIENCES LTD (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), SIENNA CANCER DIAGNOSTICS LTD (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), BENITEC BIOPHARMA LTD (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), BIOXYNE LIMITED (ASX), HAO WEN HLDGS (HKEx), MEDIBIO LIMITED (ASX), LIVING CELL TECHNOLOGIES (ASX), AIM IMMUNOTECH INC (NYSE American), MGRC (Bursa), QT Vascular (SGX), TBG DIAGNOSTICS LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), NANOLLOSE LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), BPH ENERGY LIMITED (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.025
+0.30 %
10 Days -+0.160
+1.95 %
20 Days --0.045
-0.53 %
Medium Term Return 3 Months -+0.055
+0.66 %
6 Months --3.230
-27.84 %
1 Year --3.250
-27.97 %
Long Term Return 2 Years --9.380
-52.85 %
3 Years -+4.720
+129.32 %
5 Years --5.040
-37.58 %
Annualised Return Annualised --
-9.00 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 6.260 - 13.910 Change From 1 Year Low +2.110 % Change From 1 Year Low (%) +33.71
Change From 1 Year High -5.540 % Change From 1 Year High (%) -39.83
2 Years Range 6.260 - 27.500 Change From 2 Years Low +2.110 % Change From 2 Years Low (%) +33.71
Change From 2 Years High -19.130 % Change From 2 Years High (%) -69.56
5 Years Range 2.650 - 27.500 Change From 5 Years Low +5.720 % Change From 5 Years Low (%) +215.85
Change From 5 Years High -19.130 % Change From 5 Years High (%) -69.56
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Sangamo Therapeutics, Inc. engages in researching and developing transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

Historical Price Data

Date Open High Low Close Volume VWAP
17 Jan 2020 8.970 8.980 8.320 8.370 1,686,375 -
16 Jan 2020 8.900 9.040 8.760 8.845 1,233,508 -
15 Jan 2020 8.650 9.060 8.630 8.790 1,748,167 -
14 Jan 2020 8.240 8.655 8.110 8.640 1,868,514 -
13 Jan 2020 8.350 8.360 8.065 8.280 1,441,613 -
10 Jan 2020 8.550 8.680 8.330 8.345 1,561,127 -
09 Jan 2020 8.450 8.665 8.360 8.495 1,201,003 -
08 Jan 2020 8.190 8.395 8.140 8.340 1,000,785 -
07 Jan 2020 8.300 8.380 8.160 8.190 1,358,458 -
06 Jan 2020 8.120 8.290 7.970 8.290 1,501,725 -
03 Jan 2020 8.050 8.300 7.980 8.210 1,282,631 -
02 Jan 2020 8.430 8.440 8.120 8.210 1,397,324 -
31 Dec 2019 8.110 8.475 8.060 8.370 1,622,938 -
30 Dec 2019 8.290 8.310 7.945 8.150 1,838,526 -
27 Dec 2019 8.550 8.610 8.310 8.360 1,512,692 -
26 Dec 2019 8.830 8.830 8.440 8.530 1,336,456 -
24 Dec 2019 8.980 8.980 8.660 8.840 776,322 -
23 Dec 2019 8.420 9.195 8.350 8.950 3,104,463 -
20 Dec 2019 8.660 8.690 8.345 8.415 2,501,124 -
19 Dec 2019 8.430 8.690 8.380 8.660 1,439,318 -
18 Dec 2019 8.270 8.510 8.210 8.410 1,735,961 -
17 Dec 2019 8.370 8.420 7.860 8.240 2,771,221 -
Summary
Current 2 Weeks
(06 Jan 2020 to 17 Jan 2020)
8.120 9.060 7.970 8.370 14,601,275 -
Previous 2 Weeks
(19 Dec 2019 to 03 Jan 2020)
8.430 9.060 7.970 8.210 16,811,794 -
4 Weeks from
(20 Nov 2019 to 18 Dec 2019)
9.600 9.960 7.970 8.410 42,593,444 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.